Scarica l'app Stockscreener
3.5478
1.18%
-0.0422
Newcelx Ltd Borsa (NCEL) Ultime notizie
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05Community Driven Stock Picks - Newser
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
NCEL | NewcelX Ltd. Ordinary Shares Insider Trading - Quiver Quantitative
NewcelX Ltd. announced that it has received $1.349994 million in funding - marketscreener.com
NCEL - Finviz
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program - TipRanks
Newcelx Reports Financial Results for 2025 an - Moomoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - The Manila Times
NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans - Quiver Quantitative
NewcelX makes Type 1 diabetes program its 2026 flagship - Stock Titan
Insider Buying: Olivier Samuel Acquires 81,818 Shares of NewcelX Ltd (NCEL) - GuruFocus
NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
NewcelX (NCEL) 20-F: Kadimastem merger, heavy losses and funding risk - Stock Titan
NewcelX Ltd. (NCEL) Stock Price Today - MEXC Exchange
NCEL Should I Buy - Intellectia AI
NewcelX (NCEL) Trend Analysis | Q1 2025: Earnings ReportDividend Report - Cổng thông tin điện tử tỉnh Lào Cai
NewcelX updates presentation on diabetes therapy collaboration By Investing.com - Investing.com India
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program - marketscreener.com
NewcelX Highlights Type 1 Diabetes Flagship and Eledon Collaboration in Updated April 2026 Presentation - TipRanks
NewcelX updates presentation on diabetes therapy collaboration - Investing.com
NewcelX Ltd. Enhances Type 1 Diabetes Program with Strategic Collaboration with Eledon Pharmaceuticals - Quiver Quantitative
[6-K] NewcelX Ltd. Current Report (Foreign Issuer) | NCEL SEC FilingForm 6-K - Stock Titan
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - The Manila Times
NewcelX heads to Swiss Biotech with a Type 1 diabetes strategy - Stock Titan
NewcelX (NCEL) Stock Equalweight (Runs Up) 2026-04-18High Interest Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Liora Oren Net Worth (2026) - GuruFocus
Eran Israel Iohan Net Worth (2026) - GuruFocus
Olivier Samuel Net Worth (2026) - GuruFocus
Tamar Galili Net Worth (2026) - GuruFocus
Alexander Zwyer Net Worth (2026) - GuruFocus
Ronen Twito Net Worth (2026) - GuruFocus
Kfir Molakandov Net Worth (2026) - GuruFocus
Michel Revel Net Worth (2026) - GuruFocus
Omri Hagai Net Worth (2026) - GuruFocus
Should I Buy NewcelX (NCEL) Stock Now | Price at $2.58, Up 3.61%High Reward Trade - Newser
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China - Quantisnow
NewcelX Ltd. (NCEL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NCEL Q1 2025 Earnings: NewcelX Ltd. Ordinary Shares reports -6.34 EPS no estimates or revenue filedROCE - Newser
Is NewcelX (NCEL) Stock Ready to Rally | Price at $2.27, Up 0.67%Breakout Stocks - Newser
NCEL SEC FilingsNewcelX Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NewcelX Ltd.Ordinary Shares (NQ: NCEL - The Chronicle-Journal
NewcelX raises $1.35M in private placement at 30% premium By Investing.com - Investing.com Australia
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program - TipRanks
NewcelX Ltd. announced that it expects to receive $1.349994 million in funding - marketscreener.com
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - bitget.com
NewcelX raises $1.35M in private placement at 30% premium - Investing.com
NewcelX Ltd. Secures $2.7 Million in Private Placement to Advance Type 1 Diabetes Program - Quiver Quantitative
NewcelX raises fresh cash for Type 1 diabetes program in premium deal - Stock Titan
Latest NLSPW NewsNLS Pharmaceutics to Participate in the Be... - Stock Titan
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):